Patent safeguards and generic manufacturing keep diabetes drugs cheap in India
Diabetologists find India's low drug prices stem from its role as a major pharma exporter and laws against patent evergreening that enable generics.
A study by diabetologists has examined why diabetes medicines cost far less in India than in many other countries, pointing to the country's position as a major pharmaceutical exporter and to legal provisions that shape how drugs are made and sold.
The findings tie affordable medication prices to two factors. The first is India's scale as an exporter of pharmaceuticals, which supports a large and competitive manufacturing base. The second is legislation that prevents "patent evergreening" — a practice by which companies seek extended protection for existing drugs through minor modifications — and permits the production of generic versions.
Together, these conditions allow generic manufacturers to enter the market and supply medicines at lower prices, the study notes. The research focuses on diabetes treatments, a category where long-term medication costs weigh heavily on patients.
The study's authors are diabetologists, and their work examines the structural reasons behind the pricing gap rather than any single policy change. It highlights how patent rules and generic production capacity interact to determine what patients pay for chronic-disease drugs.